Procarta is developing a lasting solution to the treatment of bacterial infections using a proprietary technology platform based on nanoparticulate oligonucleotide therapeutics. This project will enable better understanding of how to formulate and manufacture novel nanoparticulate antibacterials, define and fix key QC parameters, leading to a production process for scale up and entry to clinical trials. This manufacturing process will become a strong basis for developing a range of antibacterials able to combat existing and emerging nosocomial infections (MRSA and Clostridium difficile superbugs) as well as the emerging threat of Gram negative infections.